Guggenheim Initiates Coverage On ProKidney with Buy Rating, Announces Price Target of $6
Portfolio Pulse from Benzinga Newsdesk
Guggenheim has initiated coverage on ProKidney with a Buy rating and set a price target of $6.
September 10, 2024 | 9:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim has initiated coverage on ProKidney with a Buy rating and a price target of $6, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target by a reputable analyst can lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100